Neuro-oncology biotech industry progress report

被引：2
作者：
Chakraborty, Shamik [1 ,2 ]
Bodhinayake, Imithri [1 ]
Chiluwal, Amrit [2 ]
Langer, David J. [2 ,3 ]
Ruggieri, Rosamaria [1 ]
Symons, Marc [1 ]
Boockvar, John A. [1 ,2 ,3 ]
机构：
[1] Hofstra Northwell Sch Med, Feinstein Inst Med Res, Brain Tumor Biotech Ctr, Manhasset, NY USA
[2] Hofstra Northwell Sch Med, Dept Neurol Surg, Manhasset, NY USA
[3] Lenox Hill Hosp, Dept Neurol Surg & Otolaryngol Head & Neck Surg, Lenox Hill Brain Tumor Ctr, New York, NY 10021 USA
来源：
JOURNAL OF NEURO-ONCOLOGY | 2016年 / 128卷 / 01期
关键词：
Glioblastoma; Brain tumors; Biotechnology; PEPTIDE COMPLEX-96 HSPPC-96; SMALL-MOLECULE ONC201/TIC10; RADIATION-THERAPY SYSTEM; RENAL-CELL CARCINOMA; PHASE-II; INTRATUMORAL CONVERSION; RINDOPEPIMUT CDX-110; ANTICANCER AGENT; BRAIN; 5-FLUOROCYTOSINE;
D O I：
10.1007/s11060-016-2087-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The Brain Tumor Biotech Center at the Feinstein Institute for Medical Research, in collaboration with Voices Against Brain Cancer hosted The Brain Tumor Biotech Summit at in New York City in June 2015. The focus was once again on fostering collaboration between neuro-oncologist, neurosurgeons, scientists, leaders from biotechnology and pharmaceutical industries, and members of the financial community. The summit highlighted the recent advances in the treatment of brain tumor, and specifically focused on targeting of stem cells and EGFR, use of prophage and immunostimulatory vaccines, retroviral vectors for drug delivery, biologic prodrug, Cesium brachytherapy, and use of electric field to disrupt tumor cell proliferation. This article summarizes the current progress in brain tumor research as presented at 2015 The Brain Tumor Biotech Summit.
引用
收藏
页码：175 / 182
页数：8
相关论文
共 53 条
[1]   TRAIL receptor signaling and therapeutics [J].
Abdulghani, Junaid ;
El-Deiry, Wafik S. .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2010, 14 (10) :1091-1108
[2]   Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway [J].
Allen, Joshua E. ;
Krigsfeld, Gabriel ;
Patel, Luv ;
Mayes, Patrick A. ;
Dicker, David T. ;
Wu, Gen Sheng ;
El-Deiry, Wafik S. .
MOLECULAR CANCER, 2015, 14
[3]   Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10 [J].
Allen, Joshua E. ;
Prabhu, Varun V. ;
Talekar, Mala ;
van den Heuvel, A. Pieter J. ;
Lim, Bora ;
Dicker, David T. ;
Fritz, Jennifer L. ;
Beck, Adam ;
El-Deiry, Wafik S. .
CANCER RESEARCH, 2015, 75 (08) :1668-1674
[4]  
Angiochem, 2015, ANG ONC
[5]  
[Anonymous], 2015, SKAWENNATI
[6]   Targeting death and decoy receptors of the tumour-necrosis factor superfamily [J].
Ashkenazi, A .
NATURE REVIEWS CANCER, 2002, 2 (06) :420-430
[7]   Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes:: Clinical and immunologic findings [J].
Belli, F ;
Testori, A ;
Rivoltini, L ;
Maio, M ;
Andreola, G ;
Sertoli, MR ;
Gallino, G ;
Piris, A ;
Cattelan, A ;
Lazzari, I ;
Carrabba, M ;
Scita, G ;
Santantonio, C ;
Pilla, L ;
Tragni, G ;
Lombardo, C ;
Arienti, F ;
Marchianò, A ;
Queirolo, P ;
Bertolini, F ;
Cova, A ;
Lamaj, E ;
Ascani, L ;
Camerini, R ;
Corsi, M ;
Cascinelli, N ;
Lewis, JJ ;
Srivastava, P ;
Parmiani, G .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (20) :4169-4180
[8]   Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1 [J].
Bertrand, Y. ;
Currie, J-C ;
Poirier, J. ;
Demeule, M. ;
Abulrob, A. ;
Fatehi, D. ;
Stanimirovic, D. ;
Sartelet, H. ;
Castaigne, J-P ;
Beliveau, R. .
BRITISH JOURNAL OF CANCER, 2011, 105 (11) :1697-1707
[9]   Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccination for Recurrent Glioblastoma: A Phase II, Single Arm Trial [J].
Bloch, Orin ;
Parsa, Andrew T. .
NEURO-ONCOLOGY, 2014, 16 (05) :758-759
[10]  
Boockvar J, 2014, SOC NEUR ONC ANN SCI
123456